Physician profile
Ali Syed
NPI 1518386002
$14,713.72
in general payments reported to CMS, 2019-2025
46 companies · $4,471 in 2025
The $4,471 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $382 · 2021: $1,887 · 2022: $1,667 · 2023: $2,477 · 2024: $2,421 · 2025: $4,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,800 · Consulting Fee: $1,420 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,800.34 |
| Consulting Fee | $1,420.00 |
| Education | $149.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,880.67 | 2021-2025 | Nuro, Interstim, Intellis Adaptivestim |
| Coloplast Corp | $2,403.51 | 2020-2025 | Titan, Altis |
| Boston Scientific Corporation | $1,623.62 | 2019-2025 | Spaceoar Vue System - 10ml, General - Therapies, Ams 700 |
| Axonics, INC. | $665.86 | 2020-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $505.81 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $486.38 | 2023-2025 | Urolift, Solesta |
| Endo Pharmaceuticals INC. | $469.32 | 2020-2024 | Aveed, Xiaflex, Edex |
| Dendreon Pharmaceuticals LLC | $464.76 | 2021-2025 | Provenge |
| Pfizer INC. | $460.74 | 2020-2025 | |
| Procept Biorobotics Corporation | $405.78 | 2024-2025 | Aquabeam System |
| Janssen Biotech, INC. | $393.16 | 2023-2025 | Erleada |
| Urogen Pharma, INC. | $336.60 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $295.23 | 2023-2025 | |
| Endo USA, INC. | $290.84 | 2024-2025 | Xiaflex, Aveed |
| Medtronic USA, INC. | $264.61 | 2019 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $221.47 | 2025 | Nanoknife |
| Myriad Genetic Laboratories, INC. | $220.24 | 2022-2024 | Prolaris |
| Abbvie INC. | $212.93 | 2022-2025 | Botox |
| Amgen INC. | $177.48 | 2021-2022 | |
| Dornier Medtech America, INC | $168.99 | 2025 | Dornier Medtech |
| Astellas Pharma US INC | $163.98 | 2021-2025 | Xtandi, Myrbetriq |
| Olympus America INC. | $153.74 | 2023-2025 | Itind System |
| Astrazeneca Pharmaceuticals LP | $113.23 | 2021-2025 | Imfinzi |
| Myovant Sciences INC. | $112.42 | 2021-2022 | |
| Accord Healthcare, INC. | $109.21 | 2022-2025 | |
| Abbott Laboratories | $104.42 | 2022 | |
| Verity Pharmaceuticals INC. | $101.94 | 2023-2025 | Trelstar, Tlando |
| Novartis Pharmaceuticals Corporation | $96.77 | 2023-2024 | |
| Laborie Medical Technologies Corp. | $92.46 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $92.02 | 2021-2025 | Keytruda |
| C. R. Bard, INC. & Subsidiaries | $84.53 | 2023 | Bard Urinary Drainage Bag |
| Telix Pharmaceuticals | $77.07 | 2023-2025 | Illuccix |
| Urovant Sciences INC | $69.87 | 2022 | |
| Tolmar, INC. | $65.73 | 2023-2025 | Eligard |
| Bluewind Medical | $46.95 | 2025 | |
| Neotract INC. | $41.57 | 2020 | |
| Allergan, INC. | $35.33 | 2020-2021 | |
| Clarus Therapeutics INC. | $30.78 | 2021 | |
| Karl Storz Endoscopy-America | $27.85 | 2024 | Hopkins |
| Foundation Medicine, INC. | $25.80 | 2023 | |
| Ambu INC. | $23.09 | 2024 | |
| Bioprotect Medical, INC. | $23.00 | 2024 | Bioprotect Balloon Implant System |
| Tolmar Pharmaceuticals, INC. | $21.23 | 2022 | |
| Antares Pharma, INC. | $20.04 | 2024 | Xyosted |
| Rochester Medical Corporation | $16.76 | 2022 | |
| Photocure INC | $15.93 | 2024 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.